Gabrielle M Haeusler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7358606/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Costâ€effectiveness of homeâ€based care of febrile neutropenia in children with cancer. Pediatric Blood and Cancer, 2022, 69, e29469.	1.5	8
2	Antifungal use in children with acute leukaemia: state of current evidence and directions for future research. Journal of Antimicrobial Chemotherapy, 2022, 77, 1508-1524.	3.0	7
3	Prevalence and predictors of poor outcome in children with febrile neutropaenia presenting to the emergency department. EMA - Emergency Medicine Australasia, 2022, 34, 786-793.	1.1	3
4	Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia. Clinical and Translational Immunology, 2022, 11, .	3.8	5
5	Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients. European Journal of Cancer, 2022, 171, 1-9.	2.8	7
6	Diagnostic Yield of Initial and Consecutive Blood Cultures in Children With Cancer and Febrile Neutropenia. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 125-130.	1.3	12
7	Home-based care of low-risk febrile neutropenia in children—an implementation study in a tertiary paediatric hospital. Supportive Care in Cancer, 2021, 29, 1609-1617.	2.2	20
8	Electronic health record data for antimicrobial prescribing. Lancet Infectious Diseases, The, 2021, 21, 155-157.	9.1	1
9	Candidemia in Children. Pediatric Infectious Disease Journal, 2021, 40, 537-543.	2.0	14
10	Managing lowâ€risk febrile neutropenia in children in the time of <scp>COVID</scp> â€19: What matters to parents and clinicians. Journal of Paediatrics and Child Health, 2021, 57, 826-834.	0.8	7
11	Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children. Infection and Drug Resistance, 2021, Volume 14, 1283-1293.	2.7	8
12	Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality. Antibiotics, 2021, 10, 266.	3.7	23
13	Procalcitonin and Interleukin-10 May Assist in Early Prediction of Bacteraemia in Children With Cancer and Febrile Neutropenia. Frontiers in Immunology, 2021, 12, 641879.	4.8	8
14	Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10â€year review. Pediatric Blood and Cancer, 2021, 68, e29275.	1.5	10
15	Examining health-related quality of life in pediatric cancer patients with febrile neutropenia: Factors predicting poor recovery in children and their parents. EClinicalMedicine, 2021, 40, 101095.	7.1	10
16	Infliximab for Paradoxical Reactions in Pediatric Central Nervous System Tuberculosis. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 1087-1091.	1.3	8
17	SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients. European Journal of Cancer, 2021, 159, 78-86.	2.8	32
18	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Internal Medicine Journal, 2021, 51, 67-88.	0.8	36

#	Article	IF	CITATIONS
19	Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 71, 226-236.	5.8	84
20	Risk stratification in children with cancer and febrile neutropenia: A national, prospective, multicentre validation of nine clinical decision rules. EClinicalMedicine, 2020, 18, 100220.	7.1	34
21	Guidance regarding COVIDâ€19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatric Blood and Cancer, 2020, 67, e28702.	1.5	25
22	Re-evaluating and recalibrating predictors of bacterial infection in children with cancer and febrile neutropenia. EClinicalMedicine, 2020, 23, 100394.	7.1	28
23	Classification performance of administrative coding data for detection of invasive fungal infection in paediatric cancer patients. PLoS ONE, 2020, 15, e0238889.	2.5	7
24	Aminoglycoside use in paediatric febrile neutropenia – Outcomes from a nationwide prospective cohort study. PLoS ONE, 2020, 15, e0238787.	2.5	11
25	Managing haematology and oncology patients during the <scp>COVID</scp> â€19 pandemic: interim consensus guidance. Medical Journal of Australia, 2020, 212, 481-489.	1.7	107
26	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. Journal of Clinical Oncology, 2020, 38, 3205-3216.	1.6	63
27	Individual participant data validation of the PICNICC prediction model for febrile neutropenia. Archives of Disease in Childhood, 2020, 105, 439-445.	1.9	10
28	Title is missing!. , 2020, 15, e0238889.		0
29	Title is missing!. , 2020, 15, e0238889.		Ο
30	Title is missing!. , 2020, 15, e0238889.		0
31	Title is missing!. , 2020, 15, e0238889.		Ο
32	Invasive fungal infections in children with acute lymphoblastic leukaemia: Results from four Australian centres, 2003â€2013. Pediatric Blood and Cancer, 2019, 66, e27915.	1.5	34
33	Nonneutropenic fever in children with cancer: A scoping review of management and outcome. Pediatric Blood and Cancer, 2019, 66, e27634.	1.5	17
34	Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10â€year review. Pediatric Blood and Cancer, 2019, 66, e27564.	1.5	31
35	Management of fever and neutropenia in children with cancer: A survey of Australian and New Zealand practice. Journal of Paediatrics and Child Health, 2018, 54, 761-769.	0.8	20
36	Antibiotic-resistant Gram-negative Blood Stream Infections in Children With Cancer. Pediatric Infectious Disease Journal, 2018, 37, 495-498.	2.0	18

#	Article	IF	CITATIONS
37	External Validation of Six Pediatric Fever and Neutropenia Clinical Decision Rules. Pediatric Infectious Disease Journal, 2018, 37, 329-335.	2.0	15
38	The clinical utility of fluorodeoxyglucoseâ€positron emission tomography for investigation of fever in immunocompromised children. Journal of Paediatrics and Child Health, 2018, 54, 487-492.	0.8	9
39	Guideline for the Management of <i>Clostridium Difficile</i> Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. Journal of Clinical Oncology, 2018, 36, 3162-3171.	1.6	25
40	Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs. BMJ Open Quality, 2018, 7, e000355.	1.1	41
41	Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study. Supportive Care in Cancer, 2017, 25, 1923-1930.	2.2	22
42	Predicting Infectious ComplicatioNs in Children with Cancer: an external validation study. British Journal of Cancer, 2017, 117, 171-178.	6.4	31
43	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. Journal of Clinical Oncology, 2017, 35, 2082-2094.	1.6	337
44	Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer. European Journal of Cancer, 2016, 64, 101-106.	2.8	15
45	Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infectious Diseases, The, 2016, 16, e139-e152.	9.1	135
46	Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. British Journal of Cancer, 2016, 114, 623-630.	6.4	47
47	Management of fever and neutropenia in paediatric cancer patients. Current Opinion in Infectious Diseases, 2015, 28, 532-538.	3.1	22
48	Core outcomes and definitions for pediatric fever and neutropenia research: A consensus statement from an international panel. Pediatric Blood and Cancer, 2015, 62, 483-489.	1.5	55
49	Question 2: What are the risk factors for antibiotic resistant Gram-negative bacteraemia in children with cancer?. Archives of Disease in Childhood, 2015, 100, 895-898.	1.9	8
50	<i>Pneumocystis jirovecii</i> pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. Leukemia and Lymphoma, 2015, 56, 157-162.	1.3	11
51	The reporting of outcomes in studies of fever and neutropenia in children with cancer: Time for consensus. Pediatric Blood and Cancer, 2013, 60, 1563-1564.	1.5	12
52	Non-typhoidal Salmonella in Children: Microbiology, Epidemiology and Treatment. Advances in Experimental Medicine and Biology, 2013, 764, 13-26.	1.6	54
53	Lateâ€onset <i><scp>P</scp>neumocystis jirovecii</i> pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. European Journal of Haematology, 2013, 91, 157-163. 	2.2	23
54	An Updated Systematic Review and Meta-analysis of the Predictive Value of Serum Biomarkers in the Assessment of Fever During Neutropenia in Children With Cancer. Pediatric Infectious Disease Journal, 2013, 32, e390-e396.	2.0	48

#	Article	IF	CITATIONS
55	Antibiotic-resistant Gram-negative Bacteremia in Pediatric Oncology Patients—Risk Factors and Outcomes. Pediatric Infectious Disease Journal, 2013, 32, 723-726.	2.0	65
56	Question 1 Do febrile convulsions cause CSF pleocytosis?: Table 1. Archives of Disease in Childhood, 2012, 97, 172.2-175.	1.9	4
57	Hip to the heart. Lancet, The, 2012, 380, 858.	13.7	1
58	Symptomatic generalized epilepsy after HHV6 posttransplant acute limbic encephalitis in children. Epilepsia, 2012, 53, e122-6.	5.1	29